Suvorexant
- TRADE NAME: Belsomra (Merck Sharpe & Dohme)
- INDICATIONS: Insomnia
- CLASS: Orexin receptor antagonist
- HALF-LIFE: 10–22 hours
FDA APPROVAL DATE: 08/13/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: C
Contra-indicated in patients with narcolepsy.
Please login to see the rest of this drug profile
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric